权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

1/2 Drug Development and Capacity Building: A UCR/CoH-CCC Partnership

1/2 药物开发和能力建设：UCR/CoH-CCC 合作伙伴关系

基本信息

批准号：
10762157
负责人：
ERNEST MARTINEZ
金额：
$ 138.05万
依托单位：
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-09-22 至 2028-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10762157
关键词：
Address Affect African African American African American population American Award Bioinformatics Black race California Cancer Center Planning Grant Catchment Area Cell Line City of Hope Comprehensive Cancer Center Clinical Collaborations Communities Comprehensive Cancer Center Conduct Clinical Trials Core Facility County Crowding Disparity Drug Design Drug Targeting Economics Education Engineering Ensure Equity European FDA approved Faculty Fellowship Fostering Funding Goals Grant Growth Hispanic Americans Incubators Individual Infrastructure Institution Investments Joints Laboratories Latino Latino Population Los Angeles Malignant Neoplasms Master of Science Mentors Mentorship Minority Neighborhoods Not Hispanic or Latino Pharmaceutical Preparations Phase Physicians Population Population Heterogeneity Postdoctoral Fellow Prognosis Reporting Research Personnel Resources Scientist Section 8 Site Societies Students System Testing Therapeutic Agents Therapeutic Trials Toxic effect Training Training Programs Translations United States United States National Institutes of Health Universities Work anticancer research cancer health disparity clinical trial participant commercialization disparity elimination disparity reduction drug development drug discovery malignant breast neoplasm manufacturing facility medical schools men minority communities news next generation novel therapeutics phase 1 testing programs screening small molecule inhibitor success synergism therapeutic development women of color

项目摘要

The United States (U.S.) has led the world in drug discovery for over 50 years. While this is a significant accomplishment, U.S. drugs have been almost exclusively optimized and tested in non-Hispanic European- Americans and been minimally evaluated in men- or women-of-color. As a result, drugs that work well in non- Hispanic European-Americans (Anglos), may have unexpected toxicity or decreased efficacy in most of the world’s population. Disparities in U.S. drug development occur throughout the entire drug discovery pipeline. Only a small number of basic scientists are Latino/Hispanic- or African-American. Initial drug development and optimization takes place in cell lines derived from Anglos. Less than 2% of physicians conducting clinical trials are Latino/Hispanic- or African-American6. Most clinical trials participants are Anglos. Yet, new drugs are FDA approved for Latinos/Hispanics- and African-Americans/Africans without sufficient testing. It is unacceptable that drugs are developed by, and optimized for, only a fraction of our citizens. In this U54 partnership we aim to develop the resources, infrastructure, and training to mentor the next generation of researchers that reflect the diversity of our Catchment Area. Building on our successful P20 grant, here in this U54 partnership, UCR and CoHCCC aim to develop the collaborations, resources, and training programs to reduce disparities in drug development throughout the entire drug development pipeline. Our goal is for this program to become a focal point for UCR and CoHCCC to mentor and train a diverse force of cancer biologists and address the disparities in cancer therapeutics and drug development. Already, our P20 has fostered joint R01 grants, K01 grants, and pre-/post-doctoral fellowships. Both institutions are highly committed - CoHCCC contributed over $800K to our P20 grant and will contribute $250K/year to ensure the success of this U54 partnership. Aim 1 will strengthen UCR’s cancer research capacity and develop the resources to increase UCR/CoHCCC’s ability to jointly develop therapeutic agents optimized for the diverse populations in our catchment area. Aim 2 will increase the capacity of UCR and CoHCCC to jointly develop drugs that target disparities in survival affecting the diverse individuals living in our Southern California communities. Aim 3 will provide the training, opportunity, and mentorship to ensure that the next generation of therapeutic scientists and clinical trialists reflect the diversity of Southern California.

美国（美国）已经引领世界药物研发超过50年了。虽然这是一个重要的尽管如此，美国的药物几乎只在非西班牙裔欧洲人中进行了优化和测试- 美国人和最低限度的评估，在男性或女性的颜色。因此，在非- 西班牙裔欧洲裔美国人（盎格鲁人），可能有意想不到的毒性或疗效下降，在大多数世界人口。美国药物开发的差异发生在整个药物发现管道中。只有少数基础科学家是拉丁裔/西班牙裔或非洲裔美国人。最初的药物开发和优化发生在源自Anglos的细胞系中。不到2%的医生进行临床试验是拉丁裔/西班牙裔-或非洲裔美国人6.大多数临床试验参与者都是英国人。然而，新药是FDA 批准用于拉丁美洲人/西班牙裔美国人和非洲裔美国人/非洲人，无需进行充分的测试。这是不可接受药物是由我们一小部分公民开发和优化的。在U 54合作伙伴关系中，我们的目标是开发资源，基础设施和培训，以指导下一代研究人员，反映多样性我们的流域。在我们成功的P20赠款的基础上，在U 54合作伙伴关系中，UCR和 CoHCCC旨在发展合作，资源和培训计划，以减少药物的差异在整个药物开发过程中。我们的目标是让这个项目成为 UCR和CoHCCC指导和培训癌症生物学家的多元化力量并解决差异的重点在癌症治疗和药物开发方面。我们的P20已经促进了联合R 01赠款，K 01赠款，博士前/博士后研究金。这两个机构都高度致力于- CoHCCC贡献了超过80万美元， P20赠款，并将每年捐款25万美元，以确保这一U 54伙伴关系的成功。目标1将加强 UCR的癌症研究能力和开发资源，以提高UCR/CoHCCC的联合开发能力针对我们集水区的不同人群进行了优化的治疗药物。目标2将提高能力 UCR和CoHCCC联合开发针对影响不同个体生存差异的药物生活在南加州社区。目标3将提供培训、机会和指导，确保下一代治疗科学家和临床试验者反映南方的多样性加州。